Clinical Trial

A Study to Investigate Cabotegravir Ultra Long-Acting (CAB ULA) Plus Rilpivirine Ultra Long-Acting (RPV ULA) in Adults and Adolescents With HIV Who Are Virologically Suppressed

Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
This study compares the efficacy, safety and tolerability of CAB ULA and RPV ULA administered with CAB long acting (LA) and RPV LA administered in adults and adolescents with HIV who are virologically suppressed on anti-retroviral therapy (ART).
Protocol Amendment History 3 changes
notable Trial sites expanded: 54 -> 88 locations 2026-08-15
critical Recruitment opened 2026-08-04
notable Trial sites expanded: 0 -> 54 locations 2026-08-04
Trial Details
NCT Number NCT07650916
Lead Sponsor ViiV Healthcare
Conditions HIV Infections
Enrollment 564 participants
Start Date 2026-06-25
Primary Completion 2029-09-04 (estimated)
Study Completion 2029-09-04 (estimated)
Updated on ClinicalTrials.gov 2026-08-14